abstract |
The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N- {4-(2, 2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4, 5-dihydro-[1, 3, 4]thiadiazol-2-yl} -2, 2-dimethyl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form. |